Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -7.58 USD | -1622.73% |
| 2022 | -0.44 USD | 96.0% |
| 2021 | -10.99 USD | -9.57% |
| 2020 | -10.03 USD | -30.6% |
| 2019 | -7.68 USD | 40.79% |
| 2018 | -12.97 USD | -65.43% |
| 2017 | -7.84 USD | 51.93% |
| 2016 | -16.31 USD | -22.82% |
| 2015 | -13.28 USD | 10.75% |
| 2014 | -14.88 USD | 46.8% |
| 2013 | -27.97 USD | -21.61% |
| 2012 | -23.00 USD | 42.18% |
| 2011 | -39.78 USD | 43.62% |
| 2010 | -70.56 USD | -172.56% |
| 2009 | 97.24 USD | 154.74% |
| 2008 | -177.65 USD | -11.07% |
| 2007 | -159.94 USD | 32.67% |
| 2006 | -237.56 USD | 53.07% |
| 2005 | -506.19 USD | 8.24% |
| 2004 | -551.63 USD | 21.17% |
| 2003 | -699.79 USD | -54.61% |
| 2002 | -452.63 USD | -36.26% |
| 2001 | -332.17 USD | 12.49% |
| 2000 | -379.57 USD | -5.48% |
| 1999 | -359.86 USD | 19.14% |
| 1998 | -445.04 USD | 7.66% |
| 1997 | -481.96 USD | 23.13% |
| 1996 | -626.97 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.73 USD | 99.95% |
| 2024 Q2 | -0.43 USD | 41.1% |
| 2023 FY | - USD | -1622.73% |
| 2023 Q1 | -0.14 USD | -40.0% |
| 2023 Q2 | -34.00 USD | -24185.71% |
| 2023 Q3 | -1.76 USD | 94.82% |
| 2023 Q4 | -1525.07 USD | -86551.7% |
| 2022 FY | - USD | 96.0% |
| 2022 Q4 | -0.10 USD | 0.0% |
| 2022 Q1 | -1.87 USD | 54.05% |
| 2022 Q2 | -0.11 USD | 94.12% |
| 2022 Q3 | -0.10 USD | 9.09% |
| 2021 Q3 | -1.91 USD | 15.86% |
| 2021 Q4 | -4.07 USD | -113.09% |
| 2021 Q2 | -2.27 USD | 17.15% |
| 2021 Q1 | -2.74 USD | -10.48% |
| 2021 FY | - USD | -9.57% |
| 2020 Q1 | -2.27 USD | -15.23% |
| 2020 Q2 | -3.10 USD | -36.56% |
| 2020 Q4 | -2.48 USD | -7.36% |
| 2020 Q3 | -2.31 USD | 25.48% |
| 2020 FY | - USD | -30.6% |
| 2019 Q3 | -1.85 USD | 7.96% |
| 2019 Q2 | -2.01 USD | 2.9% |
| 2019 Q1 | -2.07 USD | 17.53% |
| 2019 FY | - USD | 40.79% |
| 2019 Q4 | -1.97 USD | -6.49% |
| 2018 Q3 | -2.40 USD | 47.02% |
| 2018 FY | - USD | -65.43% |
| 2018 Q1 | -3.52 USD | -115.95% |
| 2018 Q2 | -4.53 USD | -28.69% |
| 2018 Q4 | -2.51 USD | -4.58% |
| 2017 Q3 | -1.66 USD | 4.05% |
| 2017 FY | - USD | 51.93% |
| 2017 Q1 | -2.81 USD | 3.1% |
| 2017 Q2 | -1.73 USD | 38.43% |
| 2017 Q4 | -1.63 USD | 1.81% |
| 2016 FY | - USD | -22.82% |
| 2016 Q4 | -2.90 USD | 18.54% |
| 2016 Q3 | -3.56 USD | 33.08% |
| 2016 Q2 | -5.32 USD | -9.47% |
| 2016 Q1 | -4.86 USD | -18.25% |
| 2015 FY | - USD | 10.75% |
| 2015 Q1 | -3.58 USD | 10.05% |
| 2015 Q4 | -4.11 USD | -34.31% |
| 2015 Q3 | -3.06 USD | 10.26% |
| 2015 Q2 | -3.41 USD | 4.75% |
| 2014 FY | - USD | 46.8% |
| 2014 Q4 | -3.98 USD | 17.77% |
| 2014 Q3 | -4.84 USD | 28.72% |
| 2014 Q2 | -6.79 USD | -5.76% |
| 2014 Q1 | -6.42 USD | 40.83% |
| 2013 FY | - USD | -21.61% |
| 2013 Q4 | -10.85 USD | -143.82% |
| 2013 Q2 | -5.32 USD | 6.83% |
| 2013 Q3 | -4.45 USD | 16.35% |
| 2013 Q1 | -5.71 USD | 17.49% |
| 2012 FY | - USD | 42.18% |
| 2012 Q1 | -8.75 USD | 27.08% |
| 2012 Q2 | -7.27 USD | 16.91% |
| 2012 Q3 | -5.42 USD | 25.45% |
| 2012 Q4 | -6.92 USD | -27.68% |
| 2011 Q2 | -12.24 USD | 34.02% |
| 2011 Q1 | -18.55 USD | 5.21% |
| 2011 Q3 | -11.76 USD | 3.92% |
| 2011 Q4 | -12.00 USD | -2.04% |
| 2011 FY | - USD | 43.62% |
| 2010 Q3 | -19.91 USD | 37.23% |
| 2010 FY | - USD | -172.56% |
| 2010 Q1 | -23.15 USD | 3.06% |
| 2010 Q2 | -31.72 USD | -37.02% |
| 2010 Q4 | -19.57 USD | 1.71% |
| 2009 FY | - USD | 154.74% |
| 2009 Q4 | -23.88 USD | -112.75% |
| 2009 Q3 | 187.36 USD | 436.43% |
| 2009 Q2 | -55.69 USD | -34.45% |
| 2009 Q1 | -41.42 USD | -4.33% |
| 2008 Q1 | -98.32 USD | -38.19% |
| 2008 Q2 | -107.83 USD | -9.67% |
| 2008 FY | - USD | -11.07% |
| 2008 Q3 | -49.30 USD | 54.28% |
| 2008 Q4 | -39.70 USD | 19.47% |
| 2007 Q1 | -45.16 USD | 35.7% |
| 2007 Q4 | -71.15 USD | -169.38% |
| 2007 Q3 | 102.55 USD | 281.89% |
| 2007 Q2 | -56.38 USD | -24.84% |
| 2007 FY | - USD | 32.67% |
| 2006 Q1 | -111.82 USD | 17.94% |
| 2006 FY | - USD | 53.07% |
| 2006 Q4 | -70.23 USD | 3.21% |
| 2006 Q3 | -72.56 USD | 24.87% |
| 2006 Q2 | -96.58 USD | 13.63% |
| 2005 Q2 | -107.33 USD | 19.93% |
| 2005 Q1 | -134.05 USD | 14.73% |
| 2005 Q4 | -136.27 USD | 9.86% |
| 2005 Q3 | -151.17 USD | -40.85% |
| 2005 FY | - USD | 8.24% |
| 2004 Q2 | -173.16 USD | 9.96% |
| 2004 Q4 | -157.21 USD | -5.14% |
| 2004 Q3 | -149.53 USD | 13.65% |
| 2004 Q1 | -192.32 USD | -32.21% |
| 2004 FY | - USD | 21.17% |
| 2003 Q3 | -185.85 USD | -20.76% |
| 2003 Q4 | -145.47 USD | 21.73% |
| 2003 Q2 | -153.90 USD | -60.65% |
| 2003 Q1 | -95.80 USD | -1.0% |
| 2003 FY | - USD | -54.61% |
| 2002 Q4 | -94.85 USD | 3.03% |
| 2002 FY | - USD | -36.26% |
| 2002 Q1 | -70.91 USD | 20.1% |
| 2002 Q2 | -102.13 USD | -44.03% |
| 2002 Q3 | -97.81 USD | 4.23% |
| 2001 Q4 | -88.75 USD | -18.71% |
| 2001 FY | - USD | 12.49% |
| 2001 Q3 | -74.76 USD | 50.71% |
| 2001 Q2 | -151.67 USD | -121.29% |
| 2001 Q1 | -68.54 USD | 28.27% |
| 2000 Q1 | -111.64 USD | -204.45% |
| 2000 Q3 | -66.44 USD | 49.4% |
| 2000 FY | - USD | -5.48% |
| 2000 Q2 | -131.30 USD | -17.61% |
| 2000 Q4 | -95.55 USD | -43.81% |
| 1999 Q2 | -121.53 USD | -69.73% |
| 1999 Q1 | -71.60 USD | 32.11% |
| 1999 Q4 | -36.67 USD | 49.26% |
| 1999 FY | - USD | 19.14% |
| 1999 Q3 | -72.27 USD | 40.53% |
| 1998 Q1 | -155.22 USD | -2.25% |
| 1998 Q2 | -53.96 USD | 65.24% |
| 1998 Q4 | -105.47 USD | 22.83% |
| 1998 Q3 | -136.68 USD | -153.3% |
| 1998 FY | - USD | 7.66% |
| 1997 Q4 | -151.80 USD | -30.16% |
| 1997 Q3 | -116.63 USD | 0.0% |
| 1997 FY | - USD | 23.13% |
| 1996 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Appili Therapeutics Inc. | -0.03 CAD | -24194.872% |
| Eupraxia Pharmaceuticals Inc. | -1.58 CAD | -379.747% |
| Helix BioPharma Corp. | -0.21 CAD | -3509.524% |
| Microbix Biosystems Inc. | -0.00 CAD | -2526566.667% |
| Medicenna Therapeutics Corp. | -0.37 CAD | -1948.649% |
| Satellos Bioscience Inc. | -0.18 CAD | -4111.111% |
| Oncolytics Biotech Inc. | -0.41 CAD | -1748.78% |
| Sernova Corp. | -0.13 CAD | -5730.769% |